Choline Supplementation for Child Development
Trial Summary
What is the purpose of this trial?
The goal is to determine if providing a nutritional supplement, phosphatidylcholine, to pregnant women improves early brain development with improved brain-related development during the first four years of life. Participating pregnant women will receive either phosphatidylcholine or a placebo from approximately 16 weeks gestation through birth. The primary outcome is the child's behavior at four years of age as reported by the primary caregiver. Secondary outcomes include motor development, socio-emotional development, language development, and cognitive development. Potential contributors beyond the supplement, including maternal stress and placental function will also be assessed.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your healthcare provider.
What evidence supports the effectiveness of choline supplementation as a treatment for child development?
Research suggests that choline, a nutrient important for brain development, may have mild positive effects on cognitive outcomes in children, especially when used early in development. Some studies indicate that choline can help with neurodevelopmental delays and improve cognitive function in certain developmental disorders.12345
Is choline supplementation safe for children?
Choline is an essential nutrient important for growth and development, and while deficiencies can lead to health issues, the safety of supplementation in children has been studied. In one study, children with intestinal failure were given choline supplements, and no adverse effects were reported, suggesting it is generally safe. However, more research is needed to fully understand its safety profile in different populations.36789
How is choline supplementation unique as a treatment for child development?
Research Team
Camille Hoffman, MD
Principal Investigator
University of Colorado, Denver
Eligibility Criteria
This trial is for healthy pregnant women aged 18-45 with a normal BMI, who speak English or Spanish. It's not suitable for those with a history of fetal death, chronic infections like HIV, certain genetic disorders, or noncompliance issues.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either 1250 mg of choline or placebo daily from approximately 16 weeks gestation until delivery
Follow-up
Children are monitored and assessed for developmental outcomes until 4 years of age
Treatment Details
Interventions
- Choline
- Placebo
Choline is already approved in United States, European Union, Canada for the following indications:
- Dietary supplement
- Dietary supplement
- Dietary supplement
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Colorado, Denver
Lead Sponsor